



PRODUCT LIST

LIST OF PEPTIDE API

Molecules*	Therapeutic class	Stage	Commercial For
Leuprolide Acetate USP/EP	GnRH agonist and an antineoplastic agent	Commercial	ROW
Octreotide Acetate USP/EP	Treatment of Acromegaly and Carcinoid Tumors	Commercial	ROW
Ganirelix Acetate	GnRH antagonist	Commercial	ROW
Triptorelin Pamoate USP	GnRH agonist and an antineoplastic agent	Commercial	ROW
Triptorelin Acetate	GnRH agonist and an antineoplastic agent	Commercial	ROW
Cetrorelix Acetate	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Degarelix Acetate	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Goserelin acetate USP/BP	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Desmopressin USP/EP/IP	Anti-diuretic	Commercial	ROW
Exenatide USP	Antidiabetic, GLP1 receptor agonist	Commercial	ROW
Terlipressin Acetate EP	improve kidney function during hepatorenal syndrome	Commercial	ROW
Vasopressin USP/IP	Antidiuretic hormone	Commercial	ROW
Buserelin BP /IP	used in prostate cancer treatment	Commercial	ROW
Bivalirudin	Anti-coagulant/Anti-thrombin	Commercial	ROW
Glatiramer Acetate	Used in treatment of multiple sclerosis	Commercial	ROW
Atosiban Acetate IP	Labour repressant	Commercial	ROW
Carbetocin	To treat postpartum bleeding	Commercial	ROW
Eptifibatide	Used to reduce the risk of acute cardiac ischemic events	Commercial	ROW
Somatostatin EP	Antineoplastic agent against carcinoids, breast cancers, malignant lymphoma and small-cell lung cancers	Commercial	ROW

*Developed for US/Eu/ROW markets.

LIST OF PEPTIDE API

Molecules*	Therapeutic class	Stage	Commercial For
Teriparatide USP/EP/IP	Indicated for the treatment of postmenopausal women with osteoporosis	Commercial	ROW
Linaclotide	Constipation treatment	R&D Quantity Available, Scale-up completed	—
Carfilzomib	Anticancer	R&D Quantity Available, Scale-up completed	—
Etelcalcetide HCl	Used in secondary hyperparathyroidism treatment	R&D Quantity Available, Scale-up completed	—
Plecanatide	Used to treat chronic idiopathic constipation	R&D Quantity Available, Scale-up completed	—
Lanreotide Acetate	Treatment of Acromegaly	R&D Quantity Available, Scale-up completed	—
Setmelanotide	Used in treatment of obesity	R&D Quantity Available, Scale-up completed	—
Liraglutide	Type II anti-Diabetic (GLP-1)	R&D Quantity Available, Under Scale-up	—
Abaloparatide	Treatment of osteoporosis	R&D Quantity Available, Under Scale-up	—
Semaglutide	Used in treatment of Type II anti-Diabetic and obesity (GLP-1)	R&D Quantity Available, Under Scale-up	—
Difelikefalin	To treat itching during chronic kidney disease	R&D Quantity Available, Under Scale-up	—
Bremelanotide	To treat hypoactive sexual desire disorder in women	R&D Quantity Available, Under Scale-up	—
Trofinetide	Treat rett syndrom	R&D Quantity Available, Under Scale-up	—
Cagrilintide	Anti-obesity	Development completed	—
Pasireotide	Somatostatin agonists, treatment of Cushing's disease	Development completed	—
Tirzepatide	Antidiabetic (GLP-1)	Development completed	—
Retatrutide	Antidiabetic (GLP-1)	Under development	—
Vosoritide	Prescribed for the treatment of a genetic disorder called "achondroplasia"	Under development	—

*Developed for US/Eu/ROW markets.

LIST OF SEMI-SYNTHETIC API

Molecules*	Therapeutic class	Stage	Commercial For
Micafungin Sodium USP	Antifungal	Commercial	ROW
Anidulafungin Fructose	Antifungal	Commercial	ROW
Everolimus	Immunosuppressant	R&D Quantity Available, Scale-up completed	—
Obeticholic acid	Treatment of Primary Biliary Cholangitis	R&D Quantity Available, Scale-up completed	—
Midostaurin	Anticancer	R&D Quantity Available, Scale-up completed	—
Sarecycline	Antibiotic	R&D Quantity Available, Scale-up completed	—
Dalbavancin	Antibacterial	R&D Quantity Available, Under Scale-up	—
Voclosporine	Treatment of Lupus nephritis	R&D Quantity Available, Under Scale-up	—
Rezafungin Acetate	Anti Fungal	R&D Quantity Available, Under Scale-up	—
Omadacycline	Antibiotic	R&D Quantity Available, Under Scale-up	—
Ibrexafungerp Citrate	Anti Fungal	R&D Quantity Available, Under Scale-up	—

*Developed for US/Eu/ROW markets.

LIST OF OLIGONUCLEOTIDES

Molecules*	Therapeutic class	Stage	Commercial For
Nusinersen	Used in the treatment of spinal muscular atrophy (SMA)	R&D Quantity Available, Under Scale-up	—
Inclisiran	Used as Antilipemic agent	R&D Quantity Available, Under Scale-up	—
Patisiran	Used in treatment of polyneuropathy of hereditary transthyretinmediated amyloidosis in adults	R&D Quantity Available, Under Scale-up	—
Fitusiran	Used in the treatment of Hemophilia A or B	Under development	—
Lumasiran	Used in the treatment of Primary hyperoxaluria type 1	Under development	—
Nedosiran	Used in the treatment of Primary hyperoxaluria type 1	Under development	—

*Developed for US/Eu/ROW markets.

LIST OF RECOMBINANT PEPTIDES

Molecules*	Therapeutic class	Stage	Commercial For
Semaglutide	Type II anti-Diabetic (GLP – 1)	R&D Quantity Available, Scale-up completed	—
Liraglutide	Type II anti-Diabetic (GLP – 1)	R&D Quantity Available, Scale-up completed	—

*Developed for US/Eu/ROW markets.

LIST OF SYNTHETIC API

Molecules*	Therapeutic class	Stage	Commercial For
Mebendazole, Form A	Anthelmintic	R&D Quantity Available, Scale-up completed	ROW
Bedaquiline	Antituberculosis	R&D Quantity Available, Scale-up completed	ROW
Sugammadex Sodium	Reversal of neuromuscular blocker	R&D Quantity Available, Scale-up completed	—
Isavuconazonium sulfate	Antifungal	R&D Quantity Available, Scale-up completed	—
Saroglitazar Calcium	Antidiabetic	R&D Quantity Available, Scale-up completed	—
Nitisinone	For the treatment of hereditary tyrosinemia type 1	R&D Quantity Available, Scale-up completed	—
SNAC	Oral peptide absorption promoter	R&D Quantity Available, Scale-up completed	—
Deutetrabenazine	Management of chorea associated with Huntington's disease	R&D Quantity Available, Scale-up completed	—
Rufinamide	Anti-epileptic	R&D Quantity Available, Scale-up completed	—
Selexipag	Treatment of pulmonary arterial hypertension (PAH)	R&D Quantity Available, Scale-up completed	—
Vismodegib	For the treatment metastatic basal cell carcinoma	R&D Quantity Available, Scale-up completed	—
Baricitinib	For the treatment of rheumatoid arthritis.	R&D Quantity Available, Scale-up completed	—
Brexanolone	For the treatment of postpartum depression in women	R&D Quantity Available, Scale-up completed	—
Midodrine	Vasoconstrictor agent in the treatment of hypotension	R&D Quantity Available, Scale-up completed	—
Crisaborole	Antipsoriatic & a non-steroidal anti-inflammatory drug	R&D Quantity Available, Scale-up completed	—
Nintedanib Mesylate	For the treatment of idiopathic pulmonary fibrosis	R&D Quantity Available, Scale-up completed	—

*Developed for US/Eu/ROW markets.

LIST OF SYNTHETIC API

Molecules*	Therapeutic class	Stage	Commercial For
Erdafitinib	For the treatment of metastatic urothelial carcinoma	R&D Quantity Available, Scale-up completed	—
Vonoprazan	Potassium-competitive acid blocker (PCAB)	R&D Quantity Available, Scale-up completed	—
Venetoclax	For treatment of chronic lymphocytic leukemia with 17p deletion	R&D Quantity Available, Scale-up completed	—
Delamanid	Antimycobacterial	Development Completed	—
Binimetinib	For the treatment of unresectable or metastatic melanom	Development Completed	—

*Developed for US/Eu/ROW markets.

LIST OF FORMULATIONS UNDER DEVELOPMENT

LIQUID INJECTABLES

- Carbetocin injection 100 micrograms/mL in glass vials.
- Brexanolone injection, 100 mg brexanolone in 20 mL (5 mg/mL) aq.Solution.
- Sugammadex injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in a single-dose vial.
- Ganirelix Acetate injection in 1 mL prefilled glass syringe containing 250 mcg/0.5 mL as aqueous solution.
- Terlipressin injection 1 mg/10 mL in glass vials.

LYOPHILIZED INJECTIONS

- Cetrorelix Acetate for injection: 0.25 mg cetrorelix/ vial.
- Micafungin for injection, 50 mg micafungin (equivalent to 50.86 mg micafungin sodium) or 100 mg micafungin (equivalent to 101.73 mg micafungin sodium).
- Anidulafungin for injection, 50 mg & 100 mg/vial.
- Degarelix for injection 120 mg of degarelix (equivalent to the median value of 126 mg degarelix acetate) and 80 mg (equivalent to the median value of 84 mg degarelix acetate).



LIST OF FORMULATIONS UNDER DEVELOPMENT

Solid Orals tablets/ capsules.

- Sarecycline film coated tablets, 60 mg, 100 mg, and 150 mg.
- Saroglitazar Calcium tablets 2 mg and 4 mg.
- Everolimus tablet 0.25 mg.
- Desmopressin tablet 0.1 mg/0.2 mg.

Complex Generics (Oral Peptides).

- Semaglutide Tablets 3 mg, 7 mg, 14 mg.
- Linaclotide Hard Gelatin Capsule, 72 mcg, 145 mcg and 290 mcg.
- Plecanatide Tablets 3 mg.

Complex Novel Injectables.

- Triptorelin Acetate Microgranules injectable suspension 3.75mg per vial every 4 week, 11.25 mg per vial every 12 weeks; 22.5 mg per vial for every 24 weeks.
 - Leuprolide Acetate for depot suspension (lyophilized microspheres), 3.75 mg (1M), 7.5 mg (1M), 22.5 mg (3M), 30 mg (4M), and 45 mg (6M) per vial for injection.
 - Octreotide Acetate lyophilized microspheres for injectable suspension, 10 mg, 20 mg or 30 mg per vial strength.
- 



Corporate Office:

333-334, Doctor & Doctor, G.I.D.C. Makarpura,
Vadodara - 390 010, Gujarat, India.

Email: info@omgene.com | www.omgene.com